Michel Vounatsos, Biogen CEO (Photo by Dina Rudick/The Boston Globe via Getty Images)
Bleeding cash from its Alzheimer's franchise, Biogen preps 'deals of all sizes' as revenue shrivels
Biogen put out its Q4 and 2021 results today, and the numbers paint a picture of a deeply troubled big biotech with profits sliding fast …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
